AbbVie’s Skyrizi Machine Is Writing Checks Its Oncology Pipeline Now Has to Cash
Skyrizi hit $4.48B in Q1 2026 revenue. AbbVie is deploying that cash into oncology—and the CLL14 nine-year data just...
immunology cash flow
Skyrizi hit $4.48B in Q1 2026 revenue. AbbVie is deploying that cash into oncology—and the CLL14 nine-year data just...